Dr. Asif Alavi, MD

Dr. Alavi practices at Henry Ford Hospital in Detroit, Michigan, part of Henry Ford Health.

Dr. Alavi's NPI, 1790952562, was assigned on May 12, 2008. Dr. Alavi graduated from University Of Michigan Medical School in 2007. Dr. Alavi's Michigan license number on file is 4301107928.

Dr. Alavi's primary practice is Henry Ford Hospital, at 2799 W Grand Blvd, Detroit, MI 48202 in Wayne County. The practice phone is (313) 916-2600.

Dr. Alavi's primary practice is Henry Ford Hospital in Detroit, Michigan, part of Henry Ford Health. Dr. Alavi is also affiliated with Karmanos Cancer Center. The medical group on file is Henry Ford Health. Dmand AI also links Dr. Alavi to 1 more hospital and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Alavi practices, 3 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Alavi's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Alavi is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Alavi's licenses on file in 2 states: Michigan and California.

Dmand AI lists chronic anemia, chronic leukemia, deep vein thrombosis (DVT), lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Alavi treats.

CMS data shows 161 Medicare services from Dr. Alavi across 5 procedure codes in 2024, for 99 Medicare patients. Medicare paid $11,778 for them.

CMS counts 99 Medicare patients who saw Dr. Alavi in 2024. The largest group is 65 to 74, with 41 patients. 75% of them have high blood pressure, and 69% have high cholesterol. 26% are also on Medicaid. Their average risk score is 2.92, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Alavi's median patient age at 57, with 68% women.

In 2024, Dr. Alavi wrote 478 Medicare Part D claims for 62 patients. 79% of them were for generic drugs. CMS names the drug for 329 of them, across 14 drugs with 11 or more claims each, at $451,409 in total drug cost. In 2023, CMS named 180 claims across 9 drugs.

Dr. Alavi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Alavi as offering telehealth.

Dmand AI links 24 papers to Dr. Alavi, published from 2010 to 2025. 2019 was the busiest year, with 6. The most frequent topics are Hematopoietic Stem Cell Transplantation, Graft vs Host Disease and Stem Cell Transplantation. Dr. Alavi has published most often in Leuk Lymphoma. Dr. Alavi's most frequent co-authors are Lois J. Ayash, MD, Abhinav Deol, MD and Joseph P. Uberti, MD, PhD.

Dmand AI links Dr. Alavi to 10 clinical trials, 6 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Immunoglobulin Light-chain Amyloidosis, Lymphoma, Large B-Cell, Diffuse and Amyloidosis. Barbara Ann Karmanos Cancer Institute sponsors the most, 7.

CMS Open Payments shows 37 general payments to Dr. Alavi from 7 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 78% of the total. Vertex Pharmaceuticals Incorporated paid the most, $9,313.

Dmand AI lists 1 award for Dr. Alavi, most recently Commendation for Excellence in Medical Student Teaching in 2009.

Dr. Alavi graduated from University Of Michigan Medical School in 2007.

Dr. Alavi is in network with 10 carriers, including Aetna, Health Alliance Plan and Priority Health. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.